NovoCure Ltd risk profile
65 Stretched several inputs deteriorating together
Measured 21 October 2026 from NVCR's filed statements. Recomputed nightly.
65 (Stretched), driven by Cash conversion at 100, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 59 | Elevated | Volatile | One-year price volatility — 79.5% |
| Operating pressure | 42 | Elevated | Worsening | Operating-margin drift — -6.8 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.54x |
| Leverage and coverage | 84 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 71 | Stretched | Stable | Operating-margin gap against peers — -27.2 percentage points |
| Concentration | 52 | Elevated | Stable | Geographic concentration — 3,787 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.